Please provide your email address to receive an email when new articles are posted on . AI-analyzed fragmentomes and protein biomarkers better distinguished women with ovarian cancer in screening.

InterVenn Biosciences, a precision diagnostics company advancing liquid biopsy with glycoproteomics, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology ...

A study assessing an experimental cell-free DNA myelination liquid biopsy test was found to be 91% accurate at identifying early-stage epithelial ovarian cancer. A recent analysis investigating the ...

To improve ovarian cancer screening, researchers led by Johns Hopkins University’s Victor E. Velculescu, MD, PhD, developed a combination liquid biopsy approach. It has three components: measurements ...

NATICK, Mass.--(BUSINESS WIRE)--Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced it has closed a $41 million Series ...

A novel artificial intelligence (AI) protocol called DeepHRD was able to predict homologous recombination deficiency (HRD) in ovarian and breast cancers directly from routine histopathological slides.

First women’s health test marks a new chapter for InterVenn, providing access to non-invasive testing that differentiates between cancerous and benign pelvic masses for improved treatment planning ...

Analysis of data from over 1.2 million US patients with gynecologic cancers between 2004 and 2020 revealed a significant shift towards surgical de-escalation, with increased use of minimally invasive ...